Resources from the same session
How PARP inhibitors change the first-line ovarian cancer treatment
Presenter: Isabelle Ray-Coquard
Session: The treatment of ovarian cancer in 2020
Resources:
Slides
Webcast
The role of homologous recombination deficiency (HRD) and its clinical implication: Do we need it?
Presenter: David SP Tan
Session: The treatment of ovarian cancer in 2020
Resources:
Slides
Webcast
Perspectives in ovarian cancer treatment (immunotherapy focus)
Presenter: Domenica Lorusso
Session: The treatment of ovarian cancer in 2020
Resources:
Slides
Webcast
LIVE Q&A
Presenter: Domenica Lorusso
Session: The treatment of ovarian cancer in 2020
Resources:
Webcast